# Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

> **NCT05027776** · PHASE3 · RECRUITING · sponsor: **Shanghai Bovax Biotechnology Co., Ltd.** · enrollment: 1348 (estimated)

## Conditions studied

- HPV Infections
- Cervical Cancer Stage IIa
- Vaginal Cancer
- Genital Wart
- CIN1
- CIN2
- CIN3

## Interventions

- **BIOLOGICAL:** 2-doses Group among 9-14 years
- **BIOLOGICAL:** 3-doses Group among 9-19 years
- **BIOLOGICAL:** 3-doses Group among 20-26 years

## Key facts

- **NCT ID:** NCT05027776
- **Lead sponsor:** Shanghai Bovax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-15
- **Primary completion:** 2023-11-22
- **Final completion:** 2026-09-29
- **Target enrollment:** 1348 (ESTIMATED)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027776, "Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05027776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*